Although many substances have been synthesized for potential activity against viruses, very few can be used in clinical medicine. One of these is 1-aminoadamantane hydrochloride (amantadine), which has been shown to be partly effective in influenza A infections of man (10, 19, 22, 25) . As a consequence, a number of secondarily substituted adamantanes have now been produced for a study of structure-activity relationships (15) . A compound, 1'-methyl spiro (adamantane-2, 3-pyrrolidine) maleate (1: 1) ( Fig. 1) , had greater activity in tissue culture, eggs, and mice than did amantadine, weight for weight, and, also possessed a wider antiviral spectrum (F. E. Andre, unpublished data). Toxicological studies in animals and human pharmacological studies indicated that this drug was suitable for use in man when given orally. In a prophylactic trial it reduced the incidence of infections and severity of reactions of experimental Hong Kong influenza in volunteers (2) . In this paper we shall describe the testing of the drug in vitro against a range of respiratory viruses and its use on a limited scale in additional human trials. The place of adamantane compounds in viral chemoprophylaxis and chemotherapy will be considered. I (5, 11, 21) .
Titrations in tissue culture tubes. Three tubes were generally inoculated with each virus dilution. Influenza virus dilutions were 10-fold, and those for rhinoviruses and the coronavirus 229E were 3.2-fold (0.5 log10). Influenza virus end points were read by adsorption of guinea pig red cells (24) after a 4-day incubation; rhinovirus and coronavirus end points were read by cytopathic effect after a 5-day incubation.
Yield-reduction experiments. Groups of HeLa cell tubes, with or without spiroadamantane in the maintenance medium, were inoculated with about 1020 50% tissue culture-infecting doses (TCID50 Plaque assays. Plaque assays in primary bovine kidney for influenza viruses were performed by the method of Beare and Keast (3), and assays in rhinovirus-sensitive HeLa cells were performed by the method of Fiala and Kenny (7), modified by the substitution of 0.5% agarose for agar. Titers were expressed in plaque-forming units (PFU).
Trials in man. Human trials were invariably randomized and double blind (2, 20) . Briefly, in the influenza virus studies, volunteers were treated with 140 mg of spiroadamantane per day. Capsules containing 70 mg of the drug were given orally twice daily from 2 days before virus inoculation until 5 days after it. A control group received identical capsules containing an inert placebo. Trial results were assessed on the basis of the incidence and severity of clinical reactions judged by daily examination, the presence of virus in nasal secretions on the 3rd and 4th days after virus inoculation, and development of fourfold rises in antibody titer in paired sera collected before and 18 days after virus inoculation. In the rhinovirus trials, the procedure was similar except that the daily dose of drug was 120 mg (60 mg orally twice daily), and virus excretion was examined additionally on the second day after virus inoculation. There was no preliminary antibody screen to select people who were serologically susceptible to the rhinoviruses used for challenge, and a proportion of the volunteers was therefore resistant to infection with any single rhinovirus serotype. In order to achieve a satisfactory proportion of infections in the control group, a double virus challenge was therefore performed comprising 25 TCD.0 of RV2 and 50 TCD,0 of RV9 (20 (Table 4) . It seemed, therefore, that most influenza A viruses were drug sensitive but that a significant number of A strains and all influenza B viruses were drug resistant. Paramyxoviruses in tissue culture. Plaques were produced in bovine kidney monolayers by human and bovine parainfluenza type 3 viruses, but there was no plaque inhibition by a drug concentration of 32 ug/ml in the overlay medium.
Rhinovirus inhibition in tissue cultures and organ cultures. Activity against rhinoviruses, although significant, was less than against influenza A viruses. A drug dose of 32 tg/ml in the overlay medium inhibited plaque formation by five rhinovirus types in HeLa cells (Table 5 ). The amount of inhibition seen could have been due to experimental error, and because the related substance, amantadine, was inactive against picornaviruses, the experiment was repeated in tube cultures but with similar results. No enhancement of the antiviral effect was produced by initial prolonged contact between drug and cells. Yield-titration experiments (Table 6 ) also confirmed antirhinovirus activity and it appeared that RV2 was somewhat more sensitive than the other strains, a finding which influenced the subsequent choice of viruses for trials in volunteers. Nevertheless, rhinovirus inhibition was not wholly clear cut, since it appeared to depend on the type of cells used in the assay system. In MRC-5 cells (unlike HeLa cells) there was no inhibition of RV2, RV9, or RV31, and in yield-reduction experiments in human tracheal organ cultures, there was no inhibition of RV2.
Trials of the drug against rhinovirus infections of man. Because of the drug's success in experimental Hong Kong influenza in man (2), a similar trial was performed with rhinoviruses types 2 and 9. The results of these trials were compared (Table 7) . Although, as expected, the rate of infection with each individual rhinovirus was not high, a large part of the control group was infected with one or other of the two rhinoviruses. However, in contrast to the influenza trials, there was no evidence of a protective effect against rhinoviruses in man. No evidence of drug toxicity was observed in the volunteers. Coronavirus. Limited experiments were performed with the coronavirus strain 229E. Titrations in treated and untreated L132 cells suggested that the drug might possess significant activity against this virus group (Table 8) . Activity was also detected when diploid human embryo lung cells were used as the host system. infections. Hence its spectrum of activity and mode of action have been intensively studied (6, 8, 12, 14, 18, 23) . It affects an early event in the replication of influenza A viruses and exercises a consistent, if sometimes marginal, effect in vivo. In a field where so little has been achieved, the study of chemically allied substances in an attempt to define structure-activity relationships seems to be worth a special effort. This has recently proved possible because of the synthesis of a number of new adamantanes (15) , and the one which we have described in this paper, a spiroadamantane, is one of the most active and is appreciably more potent than 1-amino adamantane hydrochloride.
The results that have been obtained emphasize the problems involved in the design of broad-spectrum antiviral substances. Our drug inhibited the growth of some influenza A viruses but, like amantadine itself, was quite ineffective against influenza B viruses. Indeed, its activity against individual influenza A viruses was variable, and it produced quite different effects on viruses which were biologically similar and whose only distinguishing laboratory characteristics were their surface antigenic configurations. There is therefore no certainty that an adamantane compound which was effective in one influenza A outbreak would necessarily be so in a different outbreak. Our drug was also active in vitro against rhinoviruses, and presumably its mode of action on this group was quite different from that on the myxoviruses. To attempt to elucidate all its activities at the molecular level is not within the scope of this investigation.
There is, however, some encouragement to be derived from the study. In general, adamantane derivatives appear to produce a definite effect on members of the influenza A virus group, although this varies with different strains. Spiroadamantane also reduced the incidence and severity of experimental Hong Kong influenza in man, the virus of which was 
